Induction of multilineage markers in human myeloma cells and their down-regulation by interleukin 6

International Journal of Hematology

Volumn 85, Issue 1, 2007, Pages 49-58

  Liu, Shangqin ^a   Otsuyama, Ken Ichiro ^a   Ma, Zi ^a   Abroun, Saeid ^a   Shamsasenjan, Karim ^a   Amin, Jakia ^a   Asaoku, Hideki ^b   Kawano, Michio M ^a  

^a YAMAGUCHI UNIVERSITY GRADUATE SCHOOL OF MEDICINE   (Japan)

^b ATOMIC BOMB SURVIVORS HOSPITAL   (Japan)

Author keywords

CD33; CD7; IL 6; Multilineage markers; Multiple myeloma

Indexed keywords

BETA TUBULIN; BETA TUBULIN III; CCAAT ENHANCER BINDING PROTEIN ALPHA; CD33 ANTIGEN; CD4 ANTIGEN; CD56 ANTIGEN; CD7 ANTIGEN; CD86 ANTIGEN; COLECALCIFEROL; FORSKOLIN; GROWTH FACTOR; INTERLEUKIN 6; MESSENGER RNA; NEURON SPECIFIC ENOLASE; PERFORIN; TUMOR MARKER; UNCLASSIFIED DRUG;

ANTIGEN EXPRESSION; ARTICLE; CANCER CELL CULTURE; CANCER PATIENT; CELL GRANULE; CELL LINEAGE; CELL NUCLEUS; CELL STRUCTURE; CELL SURFACE; CONTROLLED STUDY; CYTOPLASM; DOWN REGULATION; GENE EXPRESSION; GENE EXPRESSION REGULATION; HUMAN; HUMAN CELL; MULTIPLE MYELOMA; MYELOMA CELL; NATURAL KILLER CELL; PHENOTYPE; PROTEIN EXPRESSION;

ANTIGENS, CD; BIOLOGICAL MARKERS; CELL LINE, TUMOR; CELL LINEAGE; DOWN-REGULATION; HUMANS; INTERLEUKIN-6; MULTIPLE MYELOMA; TUMOR CELLS, CULTURED;

EID: 33846653850     PISSN: 09255710     EISSN: None     Source Type: Journal    
DOI: 10.1532/IJH97.06132     Document Type: Article

References (40)

1. Adams B, Dorfler P, Aguzzi A, et al. Pax-5 encodes the transcription factor BSAP and is expressed in B lymphocytes, the developing CNS, and adult testis. Genes Dev. 1992;6:1589-1607.
2. Neurath M, Stuber ER, Strober W. BSAP: a key regulator of B-cell development and differentiation. Immunol Today. 1995;16:564-568.
3. Kozmik Z, Wang S, Dorfler P, Adams B, Busslinger M. The promoter of the CD19 gene is a target for the B-cell-specific transcription factor BSAP. Mol Cell Biol. 1992;12:2662-2672.
4. Busslinger M. Transcriptional control of early B cell development. Annu Rev Immunol. 2004;22:55-79.
5. Harada H, Kawano MM, Huang N, et al. Phenotypic difference of normal plasma cells from mature myeloma cells. Blood. 1993;81:2658-2663.
6. Mahmoud MS, Huang N, Nobuyoshi M, Lisukov IA, Tanaka H, Kawano MM. Altered expression of Pax-5 gene in human myeloma cells. Blood. 1996;87:4311-4315.
7. Walter C, Guenet J, Simon D, et al. Pax: a murine multigene family of paired box-containing genes. Genomics. 1991;11:424-434.
8. Nutt SL, Heavey B, Rolink AG, Busslinger M. Commitment to the B-lymphoid lineage depends on the transcription factor Pax-5. Nature. 1999;401:556-562.
9. Rolink AG, Nutt SL, Melchers F, Busslinger M. Long-term in vivo reconstitution of T-cell development by Pax5-deficient B-cell progenitors. Nature. 1999;401:603-606.
10. Graf T. Differentiation plasticity of hematopoietic cells. Blood. 2002;99:3089-3101.
11. Lin P, Mahdavy M, Zhan F, Katz RL, Shaughnessy JD. Expression of PAX5 in CD20-positive multiple myeloma assessed by immunohistochemistry and oligonucleotide microarray. Mod Pathol. 2004;17:1217-1222.
12. Kawano MM, Huang N, Harada H, et al. Identification of immature and mature myeloma cells in the bone marrow of human myelomas. Blood. 1993;82:564-570.
13. Li F, Tsuyama N, Ishikawa H, et al. A rapid translocation of CD45RO but not CD45RA to lipid rafts in IL-6-induced proliferation in myeloma. Blood. 2005;105:3295-3302.
14. + myeloma cells accompanied by the increased expression of VDAC-1. Oncogene. 2006:25:419-429.
15. Bodger MP, Hart DN. Molecular cloning and functional analysis of the CD33 promoter. Br J Haematol. 1998;102:986-995.
16. Zhang P, Iwasaki-Arai J, Iwasaki H, et al. Enhancement of hematopoietic stem cell repopulating capacity and self-renewal in the absence of the transcription factor C/EBPα. Immunity. 2004;21:853-863.
17. Tenen DG, Hromas R, Licht JD, Zhang DE. Transcription factors, normal myeloid development, and leukemia. Blood. 1997;90:489-519.
18. Liberg D, Smale ST, Merkenschlager M. Upstream of Ikalos. Trends Immunol. 2003;24:567-570.
19. Cao Z, Flanders K, Bertolette D, et al. Level of phosphor-Smad2/3 are sensors of the interplay between effects of TGF-β and retinoic acid on monocytic and granulocytic differentiation of HL-60 cells. Blood. 2003;101:498-507.
20. Lanier LL, Testi R, Bindl J, Phillips JH. Identity of Leu-19 (CD56) leukocyte differentiation antigen and neural cell adhesion molecule. J Exp Med. 1989;169:2233-2238.
21. di Sant' Agnese PA. Neuroendocrine differentiation in the precursors of prostate cancer. Eur Urol. 1996;30:185-190.
22. Cox ME, Deeble PD, Lakhani S, Parsons SJ. Acquisition of neuroendocrine characteristics by prostate tumor cells is reversible: implications for prostate cancer progression. Cancer Res. 1999;59:3821-3830.
23. Deeble PD, Murphy DJ, Parson SJ, Cox E. Interleukin-6- and cyclic AMP-mediated signaling potentiates neuroendocrine differentiation of LNCaP prostate tumor cells. Mol Cell Biol. 2001;21:8471-8482.
24. Kawano M, Hirano T, Matsuda T, et al. Autocrine generation and requirement of BSF-2/IL-6 for human multiple myelomas. Nature. 1988;332:83-85.
25. Klein B, Zhang X, Content J, et al. Paracrine rather than autocrine regulation of myeloma-cell growth and differentiation by interleukin-6. Blood. 1989;73:517-526.
26. Niwa H. Molecular mechanism to maintain stem cell renewal of ES cells. Cell Struct Funct. 2001;26:137-148.
27. Duperray C, Klein B, Durie BG, et al. Phenotypic analysis of human myeloma cell lines. Blood. 1989;73:566-572.
28. Van Camp B, Durie BG, Spier C, et al. Plasma cells in multiple myeloma express a natural killer cell-associated antigen: CD56 (NKH-1; Leu-19). Blood. 1990;76:377-382.
29. Hideshima T, Bergsagel PL, Kuehl WM, Anderson KC. Advances in biology of multiple myeloma: clinical applications. Blood. 2004;104:607-618.
30. Zhan F, Harden J, Kordsmeier B, et al. Global gene expression profiling of multiple myeloma, monoclonal gammopathy of undetermined significance, and normal bone marrow plasma cells. Blood. 2002;99:1745-1757.
31. Tarte K, Zhan F, De Vos J, Klein B, Shaughnessy J. Gene expression profiling of plasma cells and plasmablasts: toward a better understanding of the late stages of B-cell differentiation. Blood. 2003;102:592-600.
32. Aprikyan AA, Liles WC, Rodger E, Jonas M, Chi EY, Dale DC. Impaired survival of bone marrow hematopoietic progenitor cells in cyclic neutropenia. Blood. 2001;87:147-153.
33. Radomska HS, Huettner CS, Zhang P, Cheng T, Scadden DT, Tenen DG. CCAAT/enhancer binding protein α is a regulatory switch sufficient for induction of granulocytic development from bipotential myeloid progenitors. Mol Cell Biol. 1998;18:4301-4314.
34. Haddad R, Guardiola P, Izac B, et al. Molecular characterization of early T/NK and B-lymphoid progenitor cells in umbilical cord blood. Blood. 2004;104:3918-3926.
35. Citarella F, Felici A, Brouwer M. Interleukin-6 downregulates factor XII production by human hepatoma cell line (HepG2). Blood. 1997;90:1501-1507.
36. Foka P, Irvine SA, Kockar F, Ramji DP. Interleukin-6 represses the transcription of the CCAAT/enhancer binding protein-α gene in hepatoma cells by inhibiting its ability to autoactivate the proximal promoter region. Nucleic Acids Res. 2003;31:6722-6732.
37. Passegue E, Jamieson CH, Ailles LE, Weissman IL. Normal and leukemic hematopoiesis: are leukemias a stem cell disorder or a reacquisition of stem cell characteristics? Proc Natl Acad Sci U S A. 2003;100(suppl 1):11842-11849.
38. Reya T, Morrison SJ, Clarke MF, Weissman IL. Stem cells, cancer, and cancer stem cells. Nature. 2001;414:105-111.
39. Wagers AJ, Weissman IL. Plasticity of adult stem cells. Cell. 2004;116:639-648.
40. Michor F, Hughes TP, Iwasa Y, et al. Dynamics of chronic myeloid leukemia. Nature. 2005;435:1267-1270.